Novo Nordisk Faces a Two-Front Test: A Failed Heart Drug and a Crucial Earnings Report
Published on 08/02/2026 at 12:43 | Redaktion boerse-global.de
The Danish pharmaceutical giant Novo Nordisk enters one of its most consequential weeks of the year with a battered share price and a pipeline question mark that refuses to go away. After Friday's 8.48 percent slide — the sharpest one-day drop the stock has suffered in months — investors now turn their attention to Tuesday's first-half earnings report, which will determine whether the sell-off was a one-off reaction or the beginning of a deeper reassessment.
A Null Result That Speaks Volumes
The trigger for Friday's rout was the failure of the Phase 3 ZEUS trial, which tested the cardiovascular drug candidate Ziltivekimab in patients with narrowed arteries or chronic kidney disease. While the drug hit its biological target and inhibited the IL-6 signaling pathway as designed, it failed to significantly reduce heart attacks, strokes, or cardiovascular deaths compared with placebo. The hazard ratio came in at 0.99 — essentially no risk reduction whatsoever.
The stock closed the session at EUR 40.90, leaving it 25.45 percent below its 52-week high of EUR 54.86 reached back in January. The 14-day RSI of 41.8 suggests the market has digested the news without tipping into panic: the stock is neither oversold nor showing any immediate signs of a rebound. On a weekly basis, the shares are down 4.63 percent, and over the past month they have lost 4.83 percent.
Martin Holst Lange, the company's chief science officer, sought to frame the setback as a strategic recalibration rather than a retreat, insisting the group's commitment to cardiovascular research remains intact. Two related trials — HERMES in heart failure patients and ARTEMIS following acute heart attacks — are still running, with results expected in the first half of 2027.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Wall Street Splits on the Severity
The analyst community is divided over how much damage the ZEUS failure actually inflicts. UBS's Matthew Weston is firmly in the bearish camp: his firm had previously baked 60 percent of Ziltivekimab's potential peak sales — roughly USD 3 billion — into its valuation models. Weston argues the market reaction should be two to three times larger than the pure valuation impact, reasoning that the setback amplifies pressure on the entire research pipeline beyond the company's blockbuster weight-loss franchise.
Mizuho's Jared Holz echoes that sentiment, calling the early trial data a disappointment that could weigh on sentiment around Novo's pipeline prospects outside its obesity drugs.
Others see Friday's sell-off as overdone. Of the 26 analysts covering the stock, 18 rate it a "Hold," and the average price target implies upside of just 4.45 percent from pre-slide levels. Their logic: Ziltivekimab represented only a small slice of the portfolio — roughly 1.7 percent of Novo Nordisk's net asset value, according to UBS — and the company has explicitly reaffirmed its 2026 profit guidance. Jefferies and Citi likewise viewed the reaction as exaggerated given the drug's modest revenue contribution, while conceding that a key growth avenue beyond the obesity and diabetes core has now lost credibility.
What makes the setback strategically painful is timing. The stock had only recently stabilized after a brutal stretch in which Danish shares lost around 40 percent of their value over the previous year. A guidance raise in May, following better-than-expected Wegovy sales in the first quarter, had offered some relief. The ZEUS failure now threatens to unravel that fragile recovery.
What Tuesday's Numbers Will Reveal
The interim report due on August 5 arrives at a moment when investors need answers that the share price alone cannot provide. The numbers will show in detail how pricing pressure in the weight-loss drug market, the rollout of the Wegovy tablet, and intensifying competition from Eli Lilly are affecting the underlying business.
There is also a legal overhang that Tuesday's report will not address but investors will keep in mind. A US class action lawsuit accuses Novo Nordisk of misleading investors about the CagriSema study, and a federal judge recently ruled that parts of the case can proceed. The court found investors had plausibly argued that statements about tolerability and trial design may have been misleading — though this is far from a ruling on actual securities fraud. The company denies the allegations and says it will defend itself vigorously.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
A Stock at a Crossroads
The shares currently sit almost exactly on their 50-day moving average of EUR 40.90 — a technical level that often acts as a battleground between bulls and bears. The stock trades far closer to its 52-week low of EUR 30.25 than to its January peak, and the failed trial has stripped away one of the few narrative pillars supporting the case for diversification beyond Ozempic and Wegovy.
The company has confirmed that a non-cash impairment charge will hit the third quarter as a result of the ZEUS outcome, though the existing 2026 earnings guidance remains untouched. That distinction — between accounting reality and operational guidance — is precisely what Tuesday's report will help clarify.
For Novo Nordisk, the stakes are straightforward. A strong set of half-year numbers could arrest the slide and give investors reason to look past the ZEUS disappointment. Anything less, and the failed trial may come to be seen not as an isolated setback but as the latest chapter in a longer story of a company struggling to prove it can thrive beyond its weight-loss franchise.
Ad
Novo Nordisk Stock: New Analysis - 2 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
